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Background: Inhaled corticosteroids are a mainstay of therapy for persistent asthma, but suboptimal adherence
with twice-daily use is widespread. Fluticasone furoate (FF) is a new inhaled corticosteroid (ICS) suitable for
once-daily dosing in asthma. This study was performed to descriptively assess the efficacy and safety of two doses
of FF, with no planned formal statistical hypothesis testing.
Methods: This was a 24-week double-blind, multicentre, parallel-group study (NCT01431950). Patients aged ≥ 12
years with moderate-severe persistent asthma and uncontrolled on mid-high dose ICS were stratified by baseline
FEV1 and randomised (1:1) to treatment with FF 100 μg or 200 μg once daily in the evening. The primary endpoint
was change from baseline trough FEV1 after 24 weeks; secondary and other endpoints included peak expiratory
flow (PEF) and rescue-free and symptom-free 24-hour periods over Weeks 1–24, and Asthma Control Test™ (ACT)
score at Week 24. A pre-specified subgroup analysis of patients by randomisation strata was performed for the
primary and selected secondary and other endpoints. Safety assessments included adverse events, laboratory and
vital sign measurements, and change from baseline in 24-hour urinary cortisol at Week 24.
Results: With FF 100 μg and 200 μg, least squares mean trough FEV1 improved from baseline by 208 mL and
284 mL, respectively, at Week 24; treatment difference: 77 mL (95% CI: –39, 192). Similar improvements from baseline in
rescue- and symptom-free periods, and morning and evening PEF were observed in both groups. Patients were 42%
more likely to be well-controlled (ACT score ≥ 20) with FF 200 μg than with FF 100 μg. Slightly more patients receiving
FF 200 μg vs. FF 100 μg reported adverse events (63% vs. 59%) and events deemed treatment related (5% vs. <1%).
Seven serious adverse events (FF 200 μg 4; FF 100 μg 3) were reported, none of which were deemed treatment related.
No clinically relevant effects of either dose on 24-hour urinary cortisol were observed.
Conclusion: Improvements from baseline in trough FEV1 were observed after 24 weeks of treatment with both doses
of FF, with a numerically greater improvement in FEV1 observed in patients receiving FF 200 μg. Secondary endpoint
findings were similar between groups. No safety concerns were identified during the study.* Correspondence: ashley.woodcock@manchester.ac.uk
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Asthma is a chronic inflammatory disorder that affects
approximately 300 million individuals worldwide [1]. Effect-
ive maintenance therapy in asthma can improve lung func-
tion, minimise symptoms and reduce the likelihood of
exacerbations that can result in hospitalisation and mortality.
Anti-inflammatory medications, primarily inhaled corticoste-
roids (ICS) are the mainstay of maintenance treatment of all
severities of asthma [2]. Despite the well-documented effect-
iveness of maintenance therapy in alleviating the symptoms
of asthma in randomised controlled trials, non-adherence to
anti-inflammatory medication is a significant problem in
clinical practice, even in patients with severe asthma [3]. A500 patients 
screened
239 randomly assigned
120 assigned to 
FF 100 mcg*
108 received FF 100 mcg 















• Adverse event: 2
• Investigator discretion: 2
• Lack of efficacy: 2
• exacerbation: 1
• Lost to follow-up: 0
• Protocol deviation: 2








*One patient was randomised in error and did not receive study medicati
11 excluded due to closure
of one study site
Figure 1 Patient disposition and reasons for withdrawal from the stunumber of factors have been found to contribute to non-
adherence in this patient population, one of which is dosing
frequency [4]. Hence, an efficacious, once-daily, inhaled
ICS with a good safety profile may benefit patients and pro-
vide better outcomes in asthma management [5].
Fluticasone furoate (FF) is a new ICS in development for
the treatment of asthma and–in combination with vilan-
terol, a new long-acting beta2 agonist (LABA)–for asthma
and chronic obstructive pulmonary disease. FF is structurally
distinct from fluticasone propionate (FP) [6] and has dem-
onstrated a longer duration of action than FP in vitro [7]. In
addition, an in vitro study of the glucocorticoid receptor
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Table 1 Patient demographics and characteristics







Patient demographics (safety population)
N 119 119 238
Age, years 46.6 (15.4) 45.1 (15.8) 45.9 (15.6)
(range) (12–76) (12–70) (12–76)
Female sex, n (%) 81 (68) 79 (66) 160 (67)
White race, n (%) 101 (85) 100 (84) 201 (84)
Patient characteristics (safety population)
Duration of asthma, years 20.1 (15.9) 21.5 (15.0) 20.8 (15.4)
≥ 1 exacerbation in prior
12 months, n (%)
73 (61) 67 (56) 140 (59)
Lung function parameters (ITT population)
N 108* 111 219*
Percent reversibility FEV1 at screening,% 30.6 (16.1) 33.9 (20.6) 32.3 (18.5)
Pre-dose FEV1 at baseline, L 2.04 (0.67) 2.08 (0.65) 2.06 (0.66)
Percent predicted FEV1 at baseline,% 68.4 (14.0) 67.8 (13.3) 68.1 (13.6)
All data are mean (SD) unless otherwise stated.
*Baseline lung function data available for 107 patients in the FF 100 μg group
(218 in total).
FF = fluticasone furoate; NA = not applicable; SD = standard deviation.
Table 2 Change from baseline in trough FEV1 (L) at Week
24 (intent-to-treat population)
Trough FEV1 (Week 24) FF 100 μg FF 200 μg
(N = 108) (N = 111)
n 106 109
LS mean 2.271 2.347




FF 100 μg (95% CI) (−0.039, 0.192)
Note: analysis performed using ANCOVA with covariates of baseline, region,
sex, age and treatment. The last observation carried forward method was used
to impute missing data.
CI = confidence interval; FF = fluticasone furoate; LS = least squares; NA = not
applicable; SE = standard error.
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human lung tissue [8]. Once-daily dosing of FF is non-
inferior to the same total dose of FF given twice daily [9],
and once-daily doses of FF 100 μg and 200 μg are effective
in improving lung function and asthma symptoms in
8-week studies of patients with asthma uncontrolled on
low- or mid-dose ICS, with an acceptable safety profile
[10,11]. Once-daily FF 200 μg has been shown to produce
similar improvements in trough FEV1 to twice-daily FP
500 μg over 24 weeks in patients with moderate-severe
asthma [12] and is considered to be high-dose ICS. Once-
daily FF 100 μg has been shown to produce similar im-
provements in trough FEV1 over 24 weeks to twice-daily FP
250 μg in patients uncontrolled on low-mid dose ICS [13].
Previous data [10,14] have suggested that FF 200 μg may be
more effective than FF 100 μg in improving lung function
in more severely impaired patients (FEV1 ≤ 65% predicted).
Pharmacokinetic analysis of FF has showed that the abso-
lute bioavailability of FF is 14%, and that systemic exposure
is dose proportional. In healthy subjects, there were no ap-
parent safety issues, even at supra-therapeutic doses [15].
This was a descriptive study for which no formal hy-
pothesis testing or statistical inference was planned.
The objective of the study was to evaluate the efficacy
and safety of two strengths of once-daily FF, 100 μg and
200 μg, in a moderate-severe asthma patient population
(≥ 12 years of age) uncontrolled on mid-high dose ICS over
a 24-week period, and to descriptively assess the possibility
of a benefit of the higher strength of FF in such a patient
population. No placebo group was included in this study, as
it was not considered ethical to randomise patients with
moderate-severe asthma to receive placebo for 24 weeks.
Patients were stratified by baseline % predicted FEV1 at ran-
domisation and, in a pre-specified sub-analysis, efficacy
findings were compared between the randomisation strata.
Methods
Patients
Patients aged ≥ 12 years were eligible if they had a diag-
nosis of asthma as defined by NIH [16] for ≥ 12 weeks,
were using ICS at any dose for ≥ 12 weeks and at a
stable mid-high dose for ≥ 4 weeks prior to screening,
and demonstrated best FEV1 of 40–90% predicted and
reversibility of ≥ 12% and ≥ 200 mL with albuterol at
screening. A summary of permitted and prohibited medi-
cations, from 12 weeks prior to screening and throughout
the study, and study withdrawal criteria, are provided
in Additional file 1.
Patients entered a 4-week run-in period, during which
they used their baseline ICS at a stable dose, but stopped
any non-corticosteroid controller medication. Eligible
patients demonstrated evening pre-dose FEV1 of 40–90%
predicted, and over the last 7 days of run-in had docu-
mented use of rescue medication and/or asthma symptoms,completed the daily diary measures, and complied with
baseline medication on ≥ 4 days.
All patients gave written informed consent prior to
the performance of any study-specific procedures. The
study was approved by local ethics review committees
(Additional file 2) and was conducted in accordance with
the Declaration of Helsinki [17], Good Clinical Practice
guidelines [18] and all applicable regulatory requirements.
Study design and treatments
This Phase III, multicentre, randomised, double-blind,
parallel-group study (GSK study number: FFA114496;
clinicaltrials.gov registration number: NCT01431950)
Figure 2 Repeated-measures analysis of change from baseline in trough FEV1 (L) over 24 weeks of treatment (intent-to-treat population).
Note: repeated measures analysis adjusted for baseline, region, sex, age, treatment, visit, visit by baseline interaction, visit by treatment
interaction. CI = confidence interval; FF = fluticasone furoate; LS = least squares.
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2012. Twenty-seven centres in six countries (Argentina,
United States, Chile, Russian Federation, Mexico, France)
randomised patients.
During the run-in period, baseline safety evaluations
and measures of asthma status were completed. Eligible
patients were then stratified according to baseline FEV1
(≥ 40–≤ 65% or > 65%–≤ 90% predicted) and randomised
(1:1) within their strata, in a double-blind manner, to
receive one of two strengths of once-daily FF via the
ELLIPTA® dry powder inhaler (DPI): FF 100 μg (representing
an emitted dose from the DPI of 92 μg) or 200 μg
(representing an emitted dose of 184 μg)a.
Patients were assigned to study treatment following a
telephone call to the Registration and Medication Ordering
System (RAMOS [GlaxoSmithKline, UK]) and randomised
in accordance with a central randomisation schedule gener-
ated by the sponsor using a validated computerised system
(RandAll [GlaxoSmithKline, UK]). Study medication
was dispensed at each study visit following a telephone
call to RAMOS to obtain the next blinded treatment
pack number for each patient.
Outcome measurements
The primary endpoint was change from baseline in even-
ing pre-dose, pre-bronchodilator (trough) FEV1 measured
in the clinic after 24 weeks of treatment.
Secondary efficacy endpoints were change from baseline
in percentage of rescue-free and symptom-free 24-hour
periods over the 24-week treatment period, and change
from baseline in daily morning and evening peak expiratory
flow (PEF) averaged over the 24-week treatment period. All
secondary endpoints were assessed by twice-daily record-
ings on a hand-held electronic diary. Other endpoints
included change from baseline in Asthma Control Test™
(ACT) score, change in percentage of patients whoseasthma was controlled (ACT score ≥ 20) after 24 weeks,
incidence of on-treatment severe asthma exacerbations,
and incidence of on-treatment unscheduled asthma-related
healthcare utilisation.
Safety endpoints included the incidence of adverse
events (AEs) during the 24-week treatment period, 24-hour
urinary cortisol (UC) excretion after 24 weeks of treatment,
haematological and biochemical laboratory parameters, and
routine liver function assessments. AEs were coded using
the Medical Dictionary for Regulatory Activities to give a
preferred term and system organ class.
Statistical analysis
This was a descriptive study and no formal statistical infer-
ence was planned (i.e. no p-values were calculated, but it
was planned a priori to calculate treatment differences with
associated 95% confidence intervals [CIs] for all efficacy
endpoints). The primary and secondary efficacy endpoints
were analysed using an analysis of covariance (ANCOVA)
model with effects due to baseline measurement, region,
sex, age and treatment group. As this was designed to be a
descriptive study, no adjustments for multiple comparisons
were made. Two subgroup analyses of the primary treat-
ment comparison were specified a priori: analysis by ran-
domisation stratum and by run-in ICS use.
The safety population consisted of all patients rando-
mised to study treatment who received at least one dose of
study medication. The UC population comprised a subset
of patients from the safety population who provided urine
samples that did not have confounding factors that may
have affected the interpretation of the UC results.
Randomisation of 220 patients (110 per arm) was
planned to ensure that the half-width of the 95% CI for
the primary endpoint of mean treatment difference in
change from baseline in trough FEV1 was no larger
than 110.1 mL, on the basis of assumptions of 5%
Table 3 Statistical analysis of change from baseline in
trough FEV1 (L) at Week 24 by randomisation strata and
ICS dose during run-in (intent-to-treat population)
Trough FEV1 (Week 24) FF 100 μg FF 200 μg
(N = 108) (N = 111)
Predicted FEV1 at baseline
≥ 40% to ≤ 65%
n 45 48
LS mean at baseline 1.561 1.699
LS mean at Week 24 2.368 2.422
LS mean change from baseline (SE) 0.305 (0.074) 0.359 (0.073)
Treatment difference vs. NA 0.055
FF 100 μg (95% CI) (−0.122, 0.232)
> 65% to ≤ 90%
n 61 61
LS mean at baseline 2.387 2.372
LS mean at Week 24 2.197 2.290
LS mean change from baseline (SE) 0.134 (0.062) 0.227 (0.062)
Treatment difference vs. NA 0.093




LS mean at baseline 2.039 2.085
LS mean at Week 24 2.278 2.340
LS mean change from baseline (SE) 0.222 (0.051) 0.284 (0.047)
Treatment difference vs. NA 0.063
(−0.070, 0.195)FF 100 μg (95% CI)
High-dose
n 27 19
LS mean at baseline 2.041 1.987
LS mean at Week 24 2.228 2.360
LS mean change from baseline (SE) 0.172 (0.092) 0.304 (0.110)
Treatment difference vs. NA 0.132
FF 100 μg (95% CI) (−0.124, 0.388)
Note: Missing data were imputed using the last observation carried
forward method.
CI = confidence interval; FF = fluticasone furoate; ICS = inhaled corticosteroid;
LS = least squares; SE = standard error.
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period and a standard deviation for the primary end-
point of 405 mL (estimated from previous studies).
As a consequence of site audits conducted by the study
sponsor (GlaxoSmithKline) in connection with a previous
study, concerns regarding the quality of data supplied by
one study centre were raised. The intent-to-treat (ITT)
population therefore comprised all patients in the safety
population except for those recruited by this centre; it wasdecided to exclude these patients prior to unblinding, and
therefore this decision is not considered to have affected
the integrity of the analysis. The ITT population was the
primary population for all efficacy analyses. The per proto-
col (PP) population comprised those patients in the ITT
population who did not have protocol deviations consid-
ered to impact upon the primary efficacy analysis; the deci-
sion to exclude all or part of a patient’s data from the PP
population was made prior to unblinding.Results
Study population
Of 500 patients screened, 238 were randomised and
received at least one dose of study medication (safety
population), 219 were included in the ITT population
and, of these patients, 196 (89%) completed the study
(Figure 1). Adolescents (age 12–17 years) comprised 6% of
the ITT population. Most (82%) patients had no history of
tobacco use. Patient demographics and baseline lung func-
tion characteristics are provided in Table 1.Efficacy
Primary endpoint
Both strengths of FF were associated with improvements
in trough FEV1 of > 200 mL from baseline at Week 24
(Table 2). A numerically greater increase was observed with
FF 200 μg than with FF 100 μg (77 mL [95% CI: −39, 192]).
Repeated-measures analysis of change from baseline in
trough FEV1 over 24 weeks of treatment showed that
improvement in trough FEV1 was apparent within 2 weeks
of randomisation and was maintained throughout the treat-
ment period (Figure 2).
In a pre-specified subgroup analysis of the patients in
each randomisation stratum (Table 3), a numerically greater
increase from baseline trough FEV1 was observed with both
FF 200 μg and FF 100 μg in the patients with FEV1 ≤ 65%
predicted compared with those with > 65% predicted FEV1
at baseline. In the ≤ 65% predicted stratum, baseline FEV1
differed between the treatment groups (FF 200 μg: 1.699 L,
FF 100 μg: 1.561 L), potentially confounding the results. A
greater numerical increase at Week 24 was seen with FF
200 μg (+359 mL) compared with FF 100 μg (+305 mL) in
this stratum. In the > 65% predicted stratum, in which there
was no such imbalance in lung function at baseline, a
greater magnitude of effect was observed with FF 200 μg
(+227 mL) compared with FF 100 μg (+134 mL).
In a pre-specified subgroup analysis of patients grouped
according to their run-in ICS use (mid-dose; high-dose
[Additional file 1]), a greater effect on trough FEV1 of FF
200 μg compared with FF 100 μg was observed in those
patients using high-dose ICS during run-in (Table 3). How-
ever, the size of the subgroup was small, and the 95% CI for
the treatment difference was very wide and included zero.
Figure 3 Summary of adjusted treatment comparisons for primary, secondary and other efficacy endpoints. ACT = asthma control test;
CI = confidence interval; FF = fluticasone furoate; ITT = intent-to-treat; LOCF = last observation carried forward; OD = once daily; PEF = peak
expiratory flow; PM = evening.
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Observations from analysis of secondary and other end-
points supported the primary endpoint for both doses of
FF (Figure 3; Table 4). Improvements over 24 weeks in
percentage of rescue-free and symptom-free 24-hour pe-
riods and PEF, as well as in ACT score at Week 24, were
observed in both treatment groups.
The percentage of rescue-free 24-hour periods increased
over 24 weeks by > 20% in both treatment groups. In-
creases from baseline in rescue-free and symptom-free
24-hour periods observed in the FF 200 μg and FF
100 μg groups were, respectively, equivalent to 1.6 and 1.5
additional rescue-free days and 1.4 and 1.2 symptom-free
days per week (Table 4). Change from baseline over time
for these data is shown in Figure 4. Similar improvements
from baseline were observed with FF 200 μg and 100 μg,
respectively, for PEF (L/min) measured in the evening
(7.2, 5.9) and in the morning (13.2, 13.4) (Table 4).
In both treatment groups, clinically meaningful im-
provement from baseline in ACT score (+ > 3.0) [19]
was observed. More than half of all patients reported
well-controlled asthma (ACT score ≥ 20) after 24 weeks
of treatment with FF 200 μg (59%) and FF 100 μg (53%)
(Odds Ratio: 1.42 [95% CI: 0.76, 2.68]), increasing from
14% in both groups at baseline.
No treatment differences were observed in incidence of se-
vere asthma exacerbations or healthcare resource utilisation.
Severe exacerbations (ATS/ERS taskforce definition [20])
were reported by 13 (12%) patients in the FF 200 μg group
and 14 (13%) in the FF 100 μg group. One patient in the FF
200 μg group and two patients in the FF 100 μg groupvisited an emergency room because of severe asthma ex-
acerbations. One patient in the FF 100 μg group experi-
enced a post-treatment severe asthma exacerbation.
Healthcare resource utilisation was low and similar be-
tween treatment groups: 10 patients in the FF 100 μg
group and seven in the FF 200 μg group visited a physi-
cian’s office or practice. Of these, all but one patient in the
FF 200 μg group reported that at least one of their physi-
cian’s office or practice visits was related to a severe
asthma exacerbation. There were no asthma-related in-
patient hospitalisations.
Safety assessments
Adverse events and routine safety assessments
The incidence of overall AEs and treatment-related AEs
was slightly higher in the FF 200 μg group than in the
FF 100 μg group (Table 5). There were reports of oral or
oropharyngeal candidiasis in six patients (FF 200 μg: 5,
FF 100 μg: 1) and of pneumonia in one patient (FF 200 μg)
that were deemed by the investigator to be related to
study treatment. One patient in the FF 100 μg group
experienced two post-treatment AEs (pancytopaenia
and nasopharyngitis), neither of which were deemed
treatment related. Four patients withdrew from the
study due to an AE (FF 200 μg: cholecystitis acute and
abscess, thymoma; FF 100 μg: cataract, congestive car-
diomyopathy). Serious AEs were reported by four pa-
tients in the FF 200 μg group (cholecystitis acute and
abscess, chondropathy, thymoma, intervertebral disc
protrusion and spondylolisthesis) and three in the FF
100 μg group (chondromalacia, haemorrhagic cystitis,
Table 4 Changes from baseline in secondary efficacy
endpoints over Weeks 1–24 (intent-to-treat population)
FF 100 μg FF 200 μg
(N = 108) (N = 111)
Percentage of rescue-free 24-hour periods (Weeks 1–24)
n 108 109
Baseline 14.3 11.5
LS mean change from baseline (SE) 21.3 (3.05) 23.1 (3.03)
Treatment difference vs. FF 100 μg (95% CI) NA 1.8
(−6.7, 10.3)
Percentage of symptom-free 24-hour periods (Weeks 1–24)
n 108 109
Baseline 6.1 4.9
LS mean change from baseline (SE) 17.5 (2.80) 19.6 (2.79)
Treatment difference vs. FF 100 μg (95% CI) NA 2.1
(−5.7, 9.9)
PM peak expiratory flow (L/min) (Weeks 1–24)
n 108 109
LS mean 342.7 344.0
LS mean change from baseline (SE) 5.9 (3.26) 7.2 (3.25)
Treatment difference vs. FF 100 μg (95% CI) NA 1.3
(−7.8, 10.4)
AM peak expiratory flow (L/min) (Weeks 1–24)
n 108 109
LS mean 340.8 340.6
LS mean change from baseline (SE) 13.4 (3.22) 13.2 (3.20)
Treatment difference vs. FF 100 μg (95% CI) NA −0.2
(−9.2, 8.8)
Note: analysis performed using ANCOVA with covariates of baseline, region,
sex, age and treatment.
CI = confidence interval; FF = fluticasone furoate; LS = least squares; NA = not
applicable; SE = standard error.
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related to study treatment. No deaths occurred during the
study. No clinically relevant treatment effects on laboratory
safety tests or vital signs were observed.
Urinary cortisol assessment
Least squares geometric mean 24-hour UC excretion was
assessed in 148 patients (FF 200 μg: 80, FF 100 μg: 68; UC
population). UC excretion at Week 24 increased from base-
line in both groups. Least squares geometric mean ratios,
baseline to Week 24, were 1.09 in the FF 200 μg group and
1.15 in the FF 100 μg group (FF 200 μg vs. 100 μg: 0.95
(95% CI: 0.78, 1.17). UC measurements were within the
normal range at Week 24 in 95% of patients in the FF
200 μg group, and 90% in the FF 100 μg group. Shifts
(baseline to Week 24) from normal or low to high urinary
free cortisol were reported by three patients in the FF
200 μg group and seven in the FF 100 μg group. Therewere no shifts from normal or high to low, and no patients
had low 24-hour urinary free cortisol excretion at Week 24.
Discussion
FF 100 μg and 200 μg resulted in improvements from
baseline in lung function and symptomatic endpoints in
a population of moderate-severe asthma patients uncon-
trolled on mid-high dose ICS, and displayed an acceptable
safety profile. The AEs seen in this study were consistent
with those expected in this patient population [10,11].
There were no treatment-related serious AEs, and no safety
signals of clinical concern were seen with either dose. As in
previous studies testing clinical dosages of FF, alone [10] or
with vilanterol [21,22], there was no evidence of cortisol
suppression in patients receiving either dose.
A numerically greater effect of FF 200 μg was observed
for FEV1 and for attainment of asthma control, with simi-
lar effects seen with both doses of FF for rescue-free and
symptom-free 24-hour periods. A placebo control was not
included in this study, as FF 100 μg has previously been
shown to be superior to placebo in a number of studies
[13,23,24], and it was not thought to be ethical for patients
symptomatic on mid-high dose ICS to receive placebo for
24 weeks. The purpose of this study was to investigate
whether incremental benefits of the higher FF dose could
be seen in a population with a requirement for high-dose
ICS. In this study, it was observed that patients using
higher-dose ICS at baseline showed a comparatively
greater lung function benefit with FF 200 μg than with
FF 100 μg. Improvements from baseline were seen for
all secondary endpoints with both FF 100 μg and FF
200 μg, with little difference between treatments for
most secondary endpoints. Clinically meaningful im-
provement in ACT score was seen with both strengths
of FF in both strata, and patients treated with FF
200 μg were 42% more likely to be well controlled
(ACT score ≥ 20) after 24 weeks than those receiving
FF 100 μg. However, it is important to note that none
of the CIs for the primary and secondary treatment
comparisons excluded the null value, and the study
was not designed to statistically test for a differential
treatment effect on any efficacy endpoint.
The findings of this study should be interpreted in
light of the ongoing debate about the therapeutic options
for patients whose asthma is uncontrolled on medium-
dose ICS. Current guidelines recommend the addition of a
LABA to ongoing ICS therapy in patients uncontrolled on
medium-dose ICS [1]. While the addition of a LABA is
generally recommended, in a subset of patients an increase
in ICS dose may be more appropriate. For instance, patients
whose asthma is characterised by elevated sputum eosino-
phil levels have been found to display substantially greater
response to ICS than patients with non-eosinophilic asthma
[25]. There is evidence to suggest that increasing ICS dose
Figure 4 Change from baseline in percentage of a) rescue-free 24-hour periods and b) symptom-free 24-hour periods over Weeks 0–24
(intent-to-treat population). Note: analysis performed using ANCOVA with covariates of baseline, region, sex, age and treatment. FF = fluticasone
furoate; OD = once daily; SE = standard error.
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erbations [26]. However, the investigation of such factors
was outside the scope of the present study.
Strengths of this study include its 6-month duration and
the recruitment of patients uncontrolled on mid-high dose
ICS, who represent a patient population for whom the
prescription of high-dose ICS maintenance therapy isappropriate. A potential limitation is that the study was not
formally designed or powered to detect statistically signifi-
cant treatment differences between the two treatment
groups. As non-inferiority of FF 200 μg once daily to FP
500 μg twice daily has previously been demonstrated in
patients uncontrolled on mid-high dose ICS [13], an ac-
tive, positive-control arm was not included.
Table 5 Summary of most frequent on-treatment AEs and
serious AEs (safety population)
FF 100 μg FF 200 μg
(N = 119) (N = 119)
AEs
On-treatment 70 (59) 75 (63)
On-treatment, treatment-related* 1 (< 1) 6 (5)
On-treatment, leading to withdrawal 2 (2) 2 (2)
Serious AEs
On-treatment 3 (3) 4 (3)
On-treatment AEs occurring in ≥ 5%
patients in either treatment group
Nasopharyngitis 14 (12) 15 (13)
Headache 12 (10) 15 (13)
Bronchitis 14 (12) 8 (7)
Influenza 5 (4) 8 (7)
Sinusitis 8 (7) 5 (4)
Pharyngitis 7 (6) 4 (3)
Upper respiratory tract infection 2 (2) 7 (6)
All data are n (%).
*AEs deemed treatment-related by the investigator prior to unblinding.
AE = adverse event; FF = fluticasone furoate.
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Substantial improvements from baseline in lung function,
asthma symptoms and patient-reported quality of life were
observed after 24 weeks’ dosing with both doses of once-
daily FF. Numerically greater benefit on baseline trough
FEV1 was observed in patients receiving FF 200 μg com-
pared with the lower dose, though this descriptive study
did not incorporate testing for statistical significance. The
overall safety profile of both doses of FF was good and
consistent with that seen in previous studies; no safety sig-
nals of clinical concern were identified and there was no
evidence of cortisol suppression.
Endnote
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